
Fabien Zoulim

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3470392/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE). Clinical Gastroenterology and Hepatology, 2022, 20, e784-e793.	4.4	49
2	Safety and effectiveness of up to 3 years' bulevirtide monotherapy in patients with HDV-related cirrhosis. Journal of Hepatology, 2022, 76, 464-469.	3.7	48
3	Hepatitis Delta virus in migrants: The challenge of elimination (ANRS CO22 HEPATHER cohort). Liver International, 2022, 42, 249-252.	3.9	3
4	Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis. BMC Infectious Diseases, 2022, 22, 94.	2.9	6
5	Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels. Journal of Hepatology, 2022, 76, 1042-1050.	3.7	54
6	Heparanase-1 is upregulated by hepatitis C virus and favors its replication. Journal of Hepatology, 2022, 77, 29-41.	3.7	6
7	Elevated coffee consumption is associated with a lower risk of elevated liver fibrosis biomarkers in patients treated for chronic hepatitis B (ANRS CO22 Hepather cohort). Clinical Nutrition, 2022, 41, 610-619.	5.0	8
8	Inducers of the NF-κB pathways impair hepatitis delta virus replication and strongly decrease progeny infectivity inÂvitro. JHEP Reports, 2022, 4, 100415.	4.9	3
9	Assessing immunological and virological responses in the liver: Implications for the cure of chronic hepatitis B virus infection. JHEP Reports, 2022, 4, 100480.	4.9	6
10	Prediction of hepatocellular carcinoma in Hepatitis C patients with advanced fibrosis after sustained virologic response. Clinics and Research in Hepatology and Gastroenterology, 2022, 46, 101923.	1.5	7
11	Performance of the cobas® HBV RNA automated investigational assay for the detection and quantification of circulating HBV RNA in chronic HBV patients. Journal of Clinical Virology, 2022, 150-151, 105150.	3.1	14
12	CRISPR-Cas9 Targeting of Hepatitis B Virus Covalently Closed Circular DNA Generates Transcriptionally Active Episomal Variants. MBio, 2022, 13, e0288821.	4.1	17
13	Hepatic inflammation elicits production of proinflammatory netrinâ€1 through exclusive activation of translation. Hepatology, 2022, 76, 1345-1359.	7.3	10
14	Long-Term Effectiveness, Safety, and Patient-Reported Outcomes of Self-Administered Subcutaneous Hepatitis B Immunoglobulin in Liver Post-Transplant Hepatitis B Prophylaxis: A Prospective Non-Interventional Study. Annals of Transplantation, 2022, 27, e936162.	0.9	3
15	Inflammatory Gene Expression Associates with Hepatitis B Virus cccDNA- but Not Integrant-Derived Transcripts in HBeAg Negative Disease. Viruses, 2022, 14, 1070.	3.3	8
16	HIRA Supports Hepatitis B Virus Minichromosome Establishment and Transcriptional Activity in Infected Hepatocytes. Cellular and Molecular Gastroenterology and Hepatology, 2022, 14, 527-551.	4.5	7
17	Significance of serum <scp>HBV RNA</scp> in nonâ€cirrhotic <scp>HBeAg</scp> â€negative chronic hepatitis B patients who discontinue effective antiviral therapy. Journal of Viral Hepatitis, 2022, 29, 948-957.	2.0	7
18	Preliminary Evidence for Hepatitis Delta Virus Exposure in Patients Who Are Apparently Not Infected With Hepatitis B Virus. Hepatology, 2021, 73, 861-864.	7.3	26

#	Article	IF	CITATIONS
19	Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients. Journal of Hepatology, 2021, 74, 1064-1074.	3.7	52
20	External validation of the French alphaâ€fetoprotein model for hepatocellular carcinoma liver transplantation in a recent unicentric cohort – a retrospective study. Transplant International, 2021, 34, 535-545.	1.6	2
21	HCV Eradication in Primary or Secondary Prevention Optimizes Hepatocellular Carcinoma Curative Management. Cancer Prevention Research, 2021, 14, 581-592.	1.5	2
22	Subclinical and Clinical Outcomes in Patients Coinfected With HIV and Chronic Hepatitis B Virus From Clinical Outpatient Centers in France: Protocol for an Ambispective, Longitudinal Cohort Study. JMIR Research Protocols, 2021, 10, e24731.	1.0	6
23	Molecular Crosstalk between the Hepatitis C Virus and the Extracellular Matrix in Liver Fibrogenesis and Early Carcinogenesis. Cancers, 2021, 13, 2270.	3.7	6
24	Hepatitis B virus genome diversity in adolescents: Tenofovir disoproxil fumarate treatment effect and HBeAg serocon version. Journal of Viral Hepatitis, 2021, 28, 1160-1168.	2.0	1
25	HBV 2021: New therapeutic strategies against an old foe. Liver International, 2021, 41, 15-23.	3.9	34
26	2020 position statement and recommendations of the European Liver and Intestine Transplantation Association (ELITA): management of hepatitis B virusâ€related infection before and after liver transplantation. Alimentary Pharmacology and Therapeutics, 2021, 54, 583-605.	3.7	27
27	External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV. JHEP Reports, 2021, 3, 100298.	4.9	6
28	Predictive factors for hepatocellular carcinoma in chronic hepatitis B using structural equation modeling: a prospective cohort study. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101713.	1.5	10
29	Covalently closed circular DNA: The ultimate therapeutic target for curing HBV infections. Journal of Hepatology, 2021, 75, 706-717.	3.7	57
30	Molecular Virology and Life Cycle of Hepatitis B Virus. , 2021, , 1-27.		2
31	Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial. Human Vaccines and Immunotherapeutics, 2020, 16, 388-399.	3.3	56
32	Guidance for Design and Endpoints of Clinical Trials in Chronic Hepatitis B—Report From the 2019 EASLâ€AASLD HBV Treatment Endpoints Conference. Hepatology, 2020, 71, 1070-1092.	7.3	52
33	Durability of Hepatitis B Surface Antigen Loss With Nucleotide Analogue and Peginterferon Therapy in Patients With Chronic Hepatitis B. Hepatology Communications, 2020, 4, 8-20.	4.3	43
34	Predictors of hepatitis B surface antigen loss, relapse and retreatment after discontinuation of effective oral antiviral therapy in noncirrhotic HBeAgâ€negative chronic hepatitis B. Journal of Viral Hepatitis, 2020, 27, 118-126.	2.0	38
35	Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference‡. Journal of Hepatology, 2020, 72, 539-557.	3.7	208
36	Recent advances in alcohol-related liver disease (ALD): summary of a Gut round table meeting. Gut, 2020, 69, 764-780.	12.1	112

#	Article	IF	CITATIONS
37	Correlation of serum hepatitis B core-related antigen with hepatitis B virus total intrahepatic DNA and covalently closed circular-DNA viral load in HIV–hepatitis B coinfection. Aids, 2020, 34, 1943-1949.	2.2	2
38	Hepatitis B virus preS2Δ38–55 variants: A newly identified risk factor for hepatocellular carcinoma. JHEP Reports, 2020, 2, 100144.	4.9	21
39	Progress towards elimination goals for viral hepatitis. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 533-542.	17.8	118
40	Quantification and epigenetic evaluation of the residual pool of hepatitis B covalently closed circular DNA in long-term nucleoside analogue-treated patients. Scientific Reports, 2020, 10, 21097.	3.3	26
41	Targeting hepatitis B virus with CRISPR/Cas9 approach. Journal of Hepatology, 2020, 73, S841-S842.	3.7	4
42	Two-dimensional-cultures of primary human hepatocytes allow efficient HBV infection: Old tricks still work!. Journal of Hepatology, 2020, 73, 449-451.	3.7	6
43	Sofosbuvirâ€Daclatasvir is suboptimal in patients with genotype 2 chronic hepatitis C infection: realâ€life experience from the HEPATHER ANRS CO22 cohort. Journal of Viral Hepatitis, 2020, 27, 964-973.	2.0	5
44	Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study. Gut, 2020, 69, 2214-2222.	12.1	20
45	Treatment with tenofovir disoproxil fumarate or entecavir in chronic hepatitis B virusâ€infected patients with renal impairment: results from a 7â€year, multicentre retrospective cohort study. Alimentary Pharmacology and Therapeutics, 2020, 52, 500-512.	3.7	9
46	Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis delta. Journal of Hepatology, 2020, 73, 1046-1062.	3.7	79
47	Can we cure hepatitis B virus with novel directâ€acting antivirals?. Liver International, 2020, 40, 27-34.	3.9	61
48	Full-length 5'RACE identifies all major HBV transcripts in HBV-infected hepatocytes and patient serum. Journal of Hepatology, 2020, 73, 40-51.	3.7	53
49	JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients With Chronic Infection. Gastroenterology, 2020, 159, 521-533.e9.	1.3	80
50	Direct-acting antivirals and viral RNA targeting for hepatitis B cure. Current Opinion in HIV and AIDS, 2020, 15, 165-172.	3.8	3
51	Hepatitis B virus Core protein nuclear interactome identifies SRSF10 as a host RNA-binding protein restricting HBV RNA production. PLoS Pathogens, 2020, 16, e1008593.	4.7	28
52	Hepatitis B, New Antiviral Targets. , 2020, , 122-127.		0
53	Hepatitis B virus activity in untreated hepatitis B e antigen–negative human immunodeficiency virus–hepatitis B virus co-infected patients from sub-Saharan Africa. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2019, 113, 437-445.	1.8	4
54	LARP1 binding to hepatitis C virus particles is correlated with intracellular retention of viral infectivity. Virus Research, 2019, 271, 197679.	2.2	3

#	Article	IF	CITATIONS
55	BAY 41-4109-mediated aggregation of assembled and misassembled HBV capsids in cells revealed by electron microscopy. Antiviral Research, 2019, 169, 104557.	4.1	16
56	Non-invasive biomarkers for chronic hepatitis B virus infection management. Antiviral Research, 2019, 169, 104553.	4.1	38
57	Hepatitis B virus-induced modulation of liver macrophage function promotes hepatocyte infection. Journal of Hepatology, 2019, 71, 1086-1098.	3.7	62
58	Therapeutic strategies for hepatitis B virus infection: towards a cure. Nature Reviews Drug Discovery, 2019, 18, 827-844.	46.4	352
59	Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis. Journal of Hepatology, 2019, 71, 473-485.	3.7	62
60	Update of the statements on biology and clinical impact of occult hepatitis B virus infection. Journal of Hepatology, 2019, 71, 397-408.	3.7	341
61	Hepatitis B virus mutation pattern rtL180M+A181C+M204V may contribute to entecavir resistance in clinical practice. Emerging Microbes and Infections, 2019, 8, 354-365.	6.5	15
62	A global scientific strategy to cure hepatitis B. The Lancet Gastroenterology and Hepatology, 2019, 4, 545-558.	8.1	342
63	The Potential Implication of the Autonomic Nervous System in Hepatocellular Carcinoma. Cellular and Molecular Gastroenterology and Hepatology, 2019, 8, 145-148.	4.5	4
64	Meeting the Challenge of Eliminating Chronic Hepatitis B Infection. Genes, 2019, 10, 260.	2.4	21
65	Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort. BMC Infectious Diseases, 2019, 19, 300.	2.9	5
66	Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients. Journal of Hepatology, 2019, 70, 1093-1102.	3.7	107
67	Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet, The, 2019, 393, 1453-1464.	13.7	449
68	Biological basis for functional cure of chronic hepatitis B. Journal of Viral Hepatitis, 2019, 26, 786-794.	2.0	30
69	Hepatitis B virus genotype G and liver fibrosis progression in chronic hepatitis B and human immunodeficiency virus coinfection. Journal of Medical Virology, 2019, 91, 630-641.	5.0	16
70	Primary resistance of hepatitis B virus to nucleoside and nucleotide analogues. Journal of Viral Hepatitis, 2019, 26, 278-286.	2.0	5
71	Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients. Journal of Hepatology, 2019, 70, 615-625.	3.7	204
72	Effect of hepatitis B virus (HBV) <i>surface</i> â€gene variability on markers of replication during treated human immunodeficiency virusâ€HBV infection in Western Africa. Liver International, 2019, 39, 280-289.	3.9	2

#	Article	IF	CITATIONS
73	<i>Precore</i> G1896A mutation is associated with reduced rates of HBsAg seroclearance in treated HIV hepatitis B virus coâ€infected patients from Western Africa. Journal of Viral Hepatitis, 2018, 25, 1121-1131.	2.0	9
74	Higher Mortality Despite Early Antiretroviral Therapy in Human Immunodeficiency Virus and Hepatitis B Virus (HBV)–Coinfected Patients With High HBV Replication. Clinical Infectious Diseases, 2018, 66, 112-120.	5.8	42
75	How to improve access to therapy in hepatitis B patients. Liver International, 2018, 38, 115-121.	3.9	25
76	Interaction between Toll-Like Receptor 9-CpG Oligodeoxynucleotides and Hepatitis B Virus Virions Leads to Entry Inhibition in Hepatocytes and Reduction of Alpha Interferon Production by Plasmacytoid Dendritic Cells. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	15
77	Hepatocellular carcinoma-associated depletion of the netrin-1 receptor Uncoordinated Phenotype-5A (UNC5A) skews the hepatic unfolded protein response towards prosurvival outcomes. Biochemical and Biophysical Research Communications, 2018, 495, 2425-2431.	2.1	5
78	Direct antiviral properties of TLR ligands against HBV replication in immune-competent hepatocytes. Scientific Reports, 2018, 8, 5390.	3.3	57
79	Retreatment With Sofosbuvir Plus Grazoprevir/Elbasvir Plus Ribavirin of Patients With Hepatitis C Virus Genotype 1 or 4 Who Previously Failed an NS5A- or NS3-Containing Regimen: The ANRS HC34 REVENGE Study. Clinical Infectious Diseases, 2018, 66, 1013-1018.	5.8	43
80	A research agenda for curing chronic hepatitis B virus infection. Hepatology, 2018, 67, 1127-1131.	7.3	70
81	The diverse functions of the hepatitis B core/capsid protein (HBc) in the viral life cycle: Implications for the development of HBc-targeting antivirals. Antiviral Research, 2018, 149, 211-220.	4.1	86
82	Low incidence of precore W28* mutant variants in treated hepatitis B virus and human immunodeficiency virus co-infected patients. Antiviral Research, 2018, 149, 174-178.	4.1	4
83	Inhibition of hepatitis B virus gene expression: A step towards functional cure. Journal of Hepatology, 2018, 68, 386-388.	3.7	13
84	Toll-like receptor 7 agonist GS-9620 induces prolonged inhibition of HBV via a type I interferon-dependent mechanism. Journal of Hepatology, 2018, 68, 922-931.	3.7	88
85	Hepatitis B. Nature Reviews Gastroenterology and Hepatology, 2018, , .	17.8	4
86	Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs. Gastroenterology, 2018, 155, 1436-1450.e6.	1.3	183
87	Virology and Pathogenesis of Hepatitis B. , 2018, , 464-473.e5.		1
88	Perspectives and limitations for nucleo(t)side analogs in future HBV therapies. Current Opinion in Virology, 2018, 30, 80-89.	5.4	44
89	Characterization of host and viral proteins involved in the chromatinization of the hepatitis B virus minichromosome. Journal of Hepatology, 2018, 68, S61.	3.7	1
90	Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study. Gastroenterology, 2018, 155, 431-442.e10.	1.3	81

#	Article	IF	CITATIONS
91	Characterization of Pattern Recognition Receptor Expression and Functionality in Liver Primary Cells and Derived Cell Lines. Journal of Innate Immunity, 2018, 10, 339-348.	3.8	36
92	Novel Potent Capsid Assembly Modulators Regulate Multiple Steps of the Hepatitis B Virus Life Cycle. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	83
93	Benefit of direct-acting antiviral therapy for hepatitis C virus (HCV) in monoinfected and HIV-HCV-coinfected patients with mixed cryoglobulinaemia. Clinical Microbiology and Infection, 2018, 24, 1215.e1-1215.e4.	6.0	9
94	A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-α and ribavirin for chronic hepatitis C virus infection. Virology Journal, 2018, 15, 26.	3.4	6
95	Safety, pharmakokinetics and antiviral activity of novel capsid assembly modulator (CAM) JNJ-56136379 (JNJ-6379) in treatmentnaive chronic hepatitis B (CHB) patients without cirrhosis. Journal of Hepatology, 2018, 68, S102.	3.7	17
96	Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir) Tj ETQq0 0 0 rgBT /0	Overlock 1 12.1	0 Tf 50 542 T
97	Potential effect of lamivudineâ€induced S gene mutations on liverâ€related pathogenesis in hepatitis D virus infection. Hepatology, 2017, 65, 1424-1426.	7.3	1
98	Novel targets for hepatitis B virus therapy. Liver International, 2017, 37, 33-39.	3.9	58
99	Ethics and hepatitis B cure research. Gut, 2017, 66, 389-392.	12.1	13
100	Directâ€acting antiviral therapy decreases hepatocellular carcinoma recurrence rate in cirrhotic patients with chronic hepatitis C. Liver International, 2017, 37, 1122-1127.	3.9	60
101	EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. Journal of Hepatology, 2017, 67, 370-398.	3.7	3,803
102	Poloâ€likeâ€kinase 1 is a proviral host factor for hepatitis B virus replication. Hepatology, 2017, 66, 1750-1765.	7.3	60
103	Hepatitis C virus infection propagates through interactions between Syndecan-1 and CD81 and impacts the hepatocyte glycocalyx. Cellular Microbiology, 2017, 19, e12711.	2.1	31
104	Intrahepatic innate immune response pathways are downregulated in untreated chronic hepatitis B. Journal of Hepatology, 2017, 66, 897-909.	3.7	125
105	The variability of hepatitis B envelope is associated with HBs antigen persistence in either chronic or acute HBV genotype A infection. Journal of Clinical Virology, 2017, 94, 115-122.	3.1	5
106	Challenges to a Cure for HBV Infection. Seminars in Liver Disease, 2017, 37, 231-242.	3.6	31
107	How viral genetic variants and genotypes influence disease and treatment outcome of chronic hepatitis B. Time for an individualised approach?. Journal of Hepatology, 2017, 67, 1281-1297.	3.7	132
108	Editorial overview: Antiviral strategies: Antiviral drug design: creating new ideas against old and new bugs. Current Opinion in Virology, 2017, 24, v-vii.	5.4	1

#	Article	IF	CITATIONS
109	Hepatitis B cure: From discovery to regulatory approval. Journal of Hepatology, 2017, 67, 847-861.	3.7	189
110	Hepatitis B cure: From discovery to regulatory approval. Hepatology, 2017, 66, 1296-1313.	7.3	235
111	Reciprocal antagonism between the netrin-1 receptor uncoordinated-phenotype-5A (UNC5A) and the hepatitis C virus. Oncogene, 2017, 36, 6712-6724.	5.9	9
112	Detection of the hepatitis B virus (HBV) covalently-closed-circular DNA (cccDNA) in mice transduced with a recombinant AAV-HBV vector. Antiviral Research, 2017, 145, 14-19.	4.1	49
113	Impact of deletions and mutations in Hepatitis B virus envelope proteins on serological profile and clinical evolution. Virus Research, 2017, 238, 141-147.	2.2	7
114	Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients. Journal of Hepatology, 2017, 66, 39-47.	3.7	100
115	Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications. Gastroenterology, 2017, 152, 142-156.e2.	1.3	420
116	Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination. BMC Medicine, 2017, 15, 217.	5.5	27
117	Tenofovir has inferior efficacy in adefovir-experienced chronic hepatitis B patients compared to nucleos(t)ide-naÃ ⁻ ve patients. Clinical and Molecular Hepatology, 2017, 23, 66-73.	8.9	13
118	CD81 large extracellular loop-containing fusion proteins with a dominant negative effect on HCV cell spread and replication. Journal of General Virology, 2017, 98, 1646-1657.	2.9	4
119	Epidermal Growth Factor Receptor-Dependent Mutual Amplification between Netrin-1 and the Hepatitis C Virus. PLoS Biology, 2016, 14, e1002421.	5.6	18
120	Chronic Hepatitis B Virus Infection. Journal of Clinical Gastroenterology, 2016, 50, 286-294.	2.2	42
121	Flares during longâ€ŧerm entecavir therapy in chronic hepatitis B. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 1882-1887.	2.8	10
122	Characterization of hepatitis B virus surface antigen variability and impact on <scp>HB</scp> s antigen clearance under nucleos(t)ide analogue therapy. Journal of Viral Hepatitis, 2016, 23, 387-398.	2.0	22
123	Entecavir plus tenofovir combination therapy for chronic hepatitis B in patients with previous nucleos(t)ide treatment failure. Hepatology International, 2016, 10, 779-788.	4.2	17
124	New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus. Journal of Hepatology, 2016, 64, S117-S131.	3.7	172
125	Clinical relevance of the study of hepatitis B virus covalently closed circular <scp>DNA</scp> . Liver International, 2016, 36, 72-77.	3.9	34
126	Nomogram for individualized prediction of hepatocellular carcinoma occurrence in hepatitis C virus cirrhosis (ANRS CO12 CirVir). Hepatology, 2016, 64, 1136-1147.	7.3	75

#	Article	IF	CITATIONS
127	HBV cure: why, how, when?. Current Opinion in Virology, 2016, 18, 135-143.	5.4	50
128	Sofosbuvir plus daclatasvir with or without ribavirin for chronic hepatitis C infection: Impact of drug concentration on viral load decay. Digestive and Liver Disease, 2016, 48, 1351-1356.	0.9	7
129	HDV RNA replication is associated with HBV repression and interferon-stimulated genes induction in super-infected hepatocytes. Antiviral Research, 2016, 136, 19-31.	4.1	73
130	Current treatments for chronic hepatitis B virus infections. Current Opinion in Virology, 2016, 18, 109-116.	5.4	70
131	Netrin-1 Protects Hepatocytes Against Cell Death Through Sustained Translation During the Unfolded Protein Response. Cellular and Molecular Gastroenterology and Hepatology, 2016, 2, 281-301.e9.	4.5	15
132	Decay of ccc-DNA marks persistence of intrahepatic viral DNA synthesis under tenofovir in HIV-HBV co-infected patients. Journal of Hepatology, 2016, 65, 683-691.	3.7	84
133	Glutathione peroxidase 4 is reversibly induced by HCV to control lipid peroxidation and to increase virion infectivity. Gut, 2016, 65, 144-154.	12.1	45
134	Antiviral activity of various interferons and pro-inflammatory cytokines in non-transformed cultured hepatocytes infected with hepatitis B virus. Antiviral Research, 2016, 130, 36-45.	4.1	61
135	Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year, Prospective, Real-World Study in France. Digestive Diseases and Sciences, 2016, 61, 3072-3083.	2.3	64
136	Global strategies are required to cure and eliminate HBV infection. Nature Reviews Gastroenterology and Hepatology, 2016, 13, 239-248.	17.8	134
137	Sulfur isotope analysis by MC-ICP-MS and application to small medical samples. Journal of Analytical Atomic Spectrometry, 2016, 31, 1002-1011.	3.0	30
138	Ribavirin restores IFNÎ \pm responsiveness in HCV-infected livers by epigenetic remodelling at interferon stimulated genes. Gut, 2016, 65, 672-682.	12.1	16
139	Translational Medicine in Hepatitis B Virus: What Can We Learn from Clinical Samples?. Molecular and Translational Medicine, 2016, , 167-185.	0.4	0
140	A Modelâ€Based Illustrative Exploratory Approach to Optimize the Dosing of Pegâ€IFN/RBV in Cirrhotic Hepatitis C Patients Treated With Triple Therapy. CPT: Pharmacometrics and Systems Pharmacology, 2015, 4, 37-40.	2.5	4
141	Low risk of lamivudine-resistant HBV and hepatic flares in treated HIV-HBV co-infected patients from CÑte d'Ivoire. Antiviral Therapy, 2015, 20, 643-654.	1.0	21
142	Rates and determinants of hepatitis B â€~e' antigen and hepatitis B surface antigen seroclearance during long-term follow-up of patients coinfected with HIV and hepatitis B virus. Aids, 2015, 29, 1963-1973.	2.2	42
143	Present and future therapies of hepatitis B: From discovery to cure. Hepatology, 2015, 62, 1893-1908.	7.3	269
144	The <scp>CUPIC</scp> algorithm: an accurate model for the prediction of sustained viral response under telaprevir or boceprevir triple therapy in cirrhotic patients. Journal of Viral Hepatitis, 2015, 22, 1002-1010.	2.0	0

#	Article	IF	CITATIONS
145	Antiviral Therapies and Prospects for a Cure of Chronic Hepatitis B. Cold Spring Harbor Perspectives in Medicine, 2015, 5, a021501-a021501.	6.2	128
146	Towards an HBV cure: state-of-the-art and unresolved questions—report of the ANRS workshop on HBV cure. Gut, 2015, 64, 1314-1326.	12.1	234
147	Early virological assessment during telaprevir- or boceprevir-based triple therapy in hepatitis C cirrhotic patients who failed a previous interferon based regimen–ÂThe ANRS CO20-CUPIC study. Clinics and Research in Hepatology and Gastroenterology, 2015, 39, 443-450.	1.5	5
148	Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir) Tj ETQq0 0 0 rgBT	/Oyerlock 7.3	10 Tf 50 62
149	Efficacy and safety of simeprevir with PegIFN/ribavirin in naÃ ⁻ ve or experienced patients infected with chronic HCV genotype 4. Journal of Hepatology, 2015, 62, 1047-1055.	3.7	76
150	Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians. Gut, 2015, 64, 1289-1295.	12.1	178
151	P0535 : Direct antiviral effects of various pattern recognition receptor (PRR) agonists in HBV-replicating hepatocytes. Journal of Hepatology, 2015, 62, S515-S516.	3.7	5
152	P0600 : Predictive factors of cirrhosis, hepatic decompensation and hepatocellular carcinoma in patients with chronic hepatitis delta. Journal of Hepatology, 2015, 62, S541-S542.	3.7	5
153	Can We Predict Sustained Virologic Response to Interferon $\hat{I}\pm$ Therapy in Patients With Chronic Hepatitis Delta Virus Infection?. Clinical Gastroenterology and Hepatology, 2015, 13, 2350-2352.	4.4	1
154	Early inhibition of hepatocyte innate responses by hepatitis B virus. Journal of Hepatology, 2015, 63, 1314-1322.	3.7	114
155	Expression and functionality of Toll- and RIG-like receptors in HepaRG cells. Journal of Hepatology, 2015, 63, 1077-1085.	3.7	59
156	Immune-modulators to combat hepatitis B virus infection: From IFN-α to novel investigational immunotherapeutic strategies. Antiviral Research, 2015, 122, 69-81.	4.1	56
157	Liver capsule: Validated and potential novel targets to treat hepatitis B virus. Hepatology, 2015, 62, 1619-1619.	7.3	3
158	Hepatitis C virus treatment in the real world: optimising treatment and access to therapies: TableÂ1. Gut, 2015, 64, 1824-1833.	12.1	128
159	Quantification of HBsAg in nucleos(t)ide-naÃ ⁻ ve patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study. Journal of Hepatology, 2015, 62, 56-63.	3.7	60
160	Ribavirin at the Era of Novel Direct Antiviral Agents for the Treatment of Hepatitis C Virus Infection: Relevance of Pharmacological Monitoring. Advances in Hepatology, 2014, 2014, 1-13.	1.3	10
161	Impact of lamivudine-resistance mutations on entecavir treatment outcome in hepatitis B. European Journal of Gastroenterology and Hepatology, 2014, 26, 146-154.	1.6	7

162Long-term efficacy and safety of emtricitabine plus tenofovir DF vs. tenofovir DF monotherapy in
adefovir-experienced chronic hepatitis B patients. Journal of Hepatology, 2014, 60, 715-722.3.781

#	Article	IF	CITATIONS
163	Effectiveness of Telaprevir or Boceprevir in Treatment-Experienced Patients With HCV Genotype 1 Infection and Cirrhosis. Gastroenterology, 2014, 147, 132-142.e4.	1.3	232
164	Boceprevir and telaprevirâ€based triple therapy for chronic hepatitis <scp>C</scp> : virological efficacy and impact on kidney function and model for endâ€stage liver disease score. Journal of Viral Hepatitis, 2014, 21, e98-e107.	2.0	23
165	Strategies to Inhibit Entry of HBV and HDV Into Hepatocytes. Gastroenterology, 2014, 147, 48-64.	1.3	293
166	Ultradeep Pyrosequencing and Molecular Modeling Identify Key Structural Features of Hepatitis B Virus RNase H, a Putative Target for Antiviral Intervention. Journal of Virology, 2014, 88, 574-582.	3.4	10
167	Persistent viremia in human immunodeficiency virus/hepatitis B coinfected patients undergoing long-term tenofovir: Virological and clinical implications. Hepatology, 2014, 60, 497-507.	7.3	66
168	Using Pharmacokinetic and Viral Kinetic Modeling To Estimate the Antiviral Effectiveness of Telaprevir, Boceprevir, and Pegylated Interferon during Triple Therapy in Treatment-Experienced Hepatitis C Virus-Infected Cirrhotic Patients. Antimicrobial Agents and Chemotherapy, 2014, 58, 5332-5341.	3.2	8
169	N-glycosylation mutations within hepatitis B virus surface major hydrophilic region contribute mostly to immune escape. Journal of Hepatology, 2014, 60, 515-522.	3.7	77
170	Quantification of hepatitis B e antigen between Elecsys HBeAg and Architect HBeAg assays among patients infected with hepatitis B virus. Journal of Clinical Virology, 2013, 56, 306-311.	3.1	15
171	EASL Recognition Awardee 2013. Journal of Hepatology, 2013, 59, 413-414.	3.7	0
172	Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) – NCT01514890. Journal of Hepatology, 2013, 59, 434-441.	3.7	407
173	Does occult HBV infection have an impact on the evolution of chronic hepatitis C?. Journal of Hepatology, 2013, 59, 646-647.	3.7	7
174	335 HBV INHIBITS THE AIM-2 INFLAMMASOME IN HUMAN KUPFFER CELLS. Journal of Hepatology, 2013, 58, S140.	3.7	3
175	Similar evolution of hepatitis B virus quasispecies in patients with incomplete adefovir response receiving tenofovir/emtricitabine combination or tenofovir monotherapy. Journal of Hepatology, 2013, 59, 684-695.	3.7	24
176	Kinetics of Intrahepatic Covalently Closed Circular DNA and Serum Hepatitis B Surface Antigen During Antiviral Therapy for Chronic Hepatitis B: Lessons From Experimental and Clinical Studies. Clinical Gastroenterology and Hepatology, 2013, 11, 1011-1013.	4.4	30
177	Hepatitis B virus wildâ€type and rtN236T populations show similar early HBV DNA decline in adefovir refractory patients on a tenofovirâ€based regimen. Journal of Viral Hepatitis, 2013, 20, 131-140.	2.0	23
178	Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug resistance. Liver International, 2013, 33, 116-124.	3.9	56
179	Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. Nature Reviews Drug Discovery, 2013, 12, 447-464.	46.4	925
180	High incidence of treatment-induced and vaccine-escape hepatitis B virus mutants among human immunodeficiency virus/hepatitis B-infected patients. Hepatology, 2013, 58, 912-922.	7.3	37

#	Article	IF	CITATIONS
181	Targeting Innate Immunity: A New Step in the Development of Combination Therapy for Chronic Hepatitis B. Gastroenterology, 2013, 144, 1342-1344.	1.3	22
182	Very-Low-Density Lipoprotein (VLDL)-Producing and Hepatitis C Virus-Replicating HepG2 Cells Secrete No More Lipoviroparticles than VLDL-Deficient Huh7.5 Cells. Journal of Virology, 2013, 87, 5065-5080.	3.4	34
183	HBVdb: a knowledge database for Hepatitis B Virus. Nucleic Acids Research, 2013, 41, D566-D570.	14.5	178
184	Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. Gut, 2013, 62, 760-765.	12.1	159
185	Reasons to consider earlier treatment of chronic HBV infections. Gut, 2012, 61, 333-336.	12.1	98
186	New challenges in viral hepatitis. Gut, 2012, 61, i1-i5.	12.1	24
187	Comparison between Elecsys HBsAg II and Architect HBsAg QT Assays for Quantification of Hepatitis B Surface Antigen among Patients Coinfected with HIV and Hepatitis B Virus. Vaccine Journal, 2012, 19, 242-248.	3.1	17
188	Kinetics of hepatitis B surface and envelope antigen and prediction of treatment response to tenofovir in antiretroviral-experienced HIV–hepatitis B virus-infected patients. Aids, 2012, 26, 939-949.	2.2	45
189	Management of treatment failure in chronic hepatitis B. Journal of Hepatology, 2012, 56, S112-S122.	3.7	116
190	Protease inhibitorâ€based triple therapy in chronic hepatitis C: guidelines by the French Association for the Study of the Liver. Liver International, 2012, 32, 1477-1492.	3.9	45
191	Selection of chronic hepatitis B therapy with high barrier to resistance. Lancet Infectious Diseases, The, 2012, 12, 341-353.	9.1	127
192	In vivo electroporation improves therapeutic potency of a DNA vaccine targeting hepadnaviral proteins. Virology, 2012, 433, 192-202.	2.4	11
193	Standardized One-Step Real-Time Reverse Transcription-PCR Assay for Universal Detection and Quantification of Hepatitis Delta Virus from Clinical Samples in the Presence of a Heterologous Internal-Control RNA. Journal of Clinical Microbiology, 2012, 50, 2126-2128.	3.9	28
194	Hepatitis B virus X protein stimulates gene expression selectively from extrachromosomal DNA templates. Hepatology, 2012, 56, 2116-2124.	7.3	68
195	Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: An international multicenter cohort study. Journal of Hepatology, 2012, 56, 520-526.	3.7	114
196	Decreased infectivity of nucleoside analogs-resistant hepatitis B virus mutants. Journal of Hepatology, 2012, 56, 1269-1275.	3.7	14
197	Interplay between hepatitis B virus and TLR2-mediated innate immune responses: Can restoration of TLR2 functions be a new therapeutic option?. Journal of Hepatology, 2012, 57, 486-489.	3.7	21
198	Plasmacytoid dendritic cells induce efficient stimulation of antiviral immunity in the context of chronic hepatitis B virus infection. Hepatology, 2012, 56, 1706-1718.	7.3	34

#	Article	IF	CITATIONS
199	Are novel combination therapies needed for chronic hepatitis B?. Antiviral Research, 2012, 96, 256-259.	4.1	36
200	Responseâ€guided and â€unguided treatment of chronic hepatitis <scp>C</scp> . Liver International, 2012, 32, 64-73.	3.9	12
201	Treatment of human immunodeficiency virus and hepatitis B virus infections. Haemophilia, 2012, 18, 34-37.	2.1	1
202	New approaches to the management of hepatitis C in haemophilia in 2012. Haemophilia, 2012, 18, 28-33.	2.1	21
203	Treatment failure in chronic hepatitis B. Nature Reviews Gastroenterology and Hepatology, 2011, 8, 366-367.	17.8	10
204	The life cycle of hepatitis B virus and antiviral targets. Future Virology, 2011, 6, 599-614.	1.8	11
205	Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection. Journal of Hepatology, 2011, 55, 996-1003.	3.7	361
206	269 CHARACTERISATION OF PATHOGEN RECOGNITION RECEPTORS IN AN HEPATOCYTE CELL LINE (HEPARG) Tj	ETQ900) rgBT /Overlo
207	Hepatitis B Virus Impairs TLR9 Expression and Function in Plasmacytoid Dendritic Cells. PLoS ONE, 2011, 6, e26315.	2.5	132
208	Genotypic resistance profile of hepatitis B virus (HBV) in a large cohort of nucleos(t)ide analogueâ€experienced Chinese patients with chronic HBV infection. Journal of Viral Hepatitis, 2011, 18, e29-39.	2.0	52
209	Adefovir serum levels do not differ between responders and nonresponders. Journal of Viral Hepatitis, 2011, 18, e175-8.	2.0	1
210	Hepatitis B virus resistance to antiviral drugs: where are we going?. Liver International, 2011, 31, 111-116.	3.9	118
211	Efficacy and tolerance of a combination of tenofovir disoproxil fumarate plus emtricitabine in patients with chronic hepatitis B: A European multicenter study. Antiviral Research, 2011, 92, 90-95.	4.1	22
212	The main Hepatitis B virus (HBV) mutants resistant to nucleoside analogs are susceptible in vitro to non-nucleoside inhibitors of HBV replication. Antiviral Research, 2011, 92, 271-276.	4.1	75
213	Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naÃ ⁻ ve patients with a partial virological response. Hepatology, 2011, 54, 443-451.	7.3	150

214	Molecular Genetics of HBV Infection. Antiviral Therapy, 2010, 15, 3-14.	1.0	139
215	Evolution and suppression of HBV strains with multidrug resistance to lamivudine, adefovir dipivoxil and entecavir in a patient with chronic hepatitis B. Antiviral Therapy, 2010, 15, 1185-1190.	1.0	33

Control of hepatitis B virus replication by innate response of HepaRG cells. Hepatology, 2010, 51, 63-72. 7.3 124

#	Article	IF	CITATIONS
217	Hepatitis B virus genotype and basal core promoter/precore mutations are associated with hepatitis B-related acute-on-chronic liver failure without pre-existing liver cirrhosis. Journal of Viral Hepatitis, 2010, 17, 887-895.	2.0	82
218	Innate Antiviral Immune Responses to Hepatitis B Virus. Viruses, 2010, 2, 1394-1410.	3.3	51
219	Microarray for Hepatitis B Virus Genotyping and Detection of 994 Mutations along the Genome. Journal of Clinical Microbiology, 2010, 48, 4207-4215.	3.9	20
220	End points of therapy in chronic hepatitis B. Expert Review of Gastroenterology and Hepatology, 2010, 4, 37-49.	3.0	3
221	Tenofovir Is Effective Alone or With Emtricitabine in Adefovir-Treated Patients With Chronic-Hepatitis B Virus Infection. Gastroenterology, 2010, 139, 1207-1217.e3.	1.3	133
222	Antiviral effect of entecavir in chronic hepatitis B: Influence of prior exposure to nucleos(t)ide analogues. Journal of Hepatology, 2010, 52, 493-500.	3.7	103
223	Hepatitis B virus: From diagnosis to treatment. Pathologie Et Biologie, 2010, 58, 245-253.	2.2	40
224	Innate response to hepatitis B virus infection: Observations challenging the concept of a stealth virus. Hepatology, 2009, 50, 1692-1695.	7.3	33
225	Clearance of serum HBsAg and antiâ€HBs seroconversion following antiviral therapy for chronic hepatitis B. Journal of Medical Virology, 2009, 81, 1336-1342.	5.0	34
226	Adefovir dipivoxil is effective for the treatment of cirrhotic patients with lamivudine failure. Liver International, 2009, 29, 420-426.	3.9	11
227	Management and prevention of drug resistance in chronic hepatitis B. Liver International, 2009, 29, 108-115.	3.9	34
228	Persistence of the hepatitis B virus covalently closed circular DNA in HepaRG human hepatocyte-like cells. Journal of General Virology, 2009, 90, 127-135.	2.9	128
229	In Vitro Characterization of Viral Fitness of Therapy-Resistant Hepatitis B Variants. Gastroenterology, 2009, 136, 168-176.e2.	1.3	61
230	Hepatitis B Virus Resistance to Nucleos(t)ide Analogues. Gastroenterology, 2009, 137, 1593-1608.e2.	1.3	614
231	Pathobiology of HBV mutants and clinical impact for treatment monitoring. Expert Review of Anti-Infective Therapy, 2009, 7, 309-320.	4.4	17
232	Inhibitory effect of the combination of CpG-induced cytokines with lamivudine against hepatitis B virus replication in vitro. Antiviral Therapy, 2009, 14, 131-5.	1.0	4
233	Inhibitory effect of the combination of CpG-induced cytokines with lamivudine against hepatitis B virus replication <i>in vitro</i> . Antiviral Therapy, 2009, 14, 131-135.	1.0	17
234	Management of patients with decompensated hepatitis B virus associated cirrhosis. Liver Transplantation, 2008, 14, S1-S7.	2.4	25

#	Article	IF	CITATIONS
235	Hepatitis B: Reflections on the current approach to antiviral therapy. Journal of Hepatology, 2008, 48, S2-S19.	3.7	142
236	Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. Journal of Hepatology, 2008, 48, 747-755.	3.7	180
237	Virologic Monitoring of Hepatitis B Virus Therapy in Clinical Trials and Practice: Recommendations for a Standardized Approach. Gastroenterology, 2008, 134, 405-415.	1.3	215
238	Rolling Circle Amplification, a Powerful Tool for Genetic and Functional Studies of Complete Hepatitis B Virus Genomes from Low-Level Infections and for Directly Probing Covalently Closed Circular DNA. Antimicrobial Agents and Chemotherapy, 2008, 52, 3068-3073.	3.2	54
239	Initiation of hepatitis B virus genome replication and production of infectious virus following delivery in HepG2 cells by novel recombinant baculovirus vector. Journal of General Virology, 2008, 89, 1819-1828.	2.9	41
240	DNA vaccination in combination or not with lamivudine treatment breaks humoral immune tolerance and enhances cccDNA clearance in the duck model of chronic hepatitis B virus infection. Journal of General Virology, 2008, 89, 1192-1201.	2.9	21
241	Suboptimal Response to Adefovir Dipivoxil Therapy for Chronic Hepatitis B in Nucleoside-Naive Patients is not due to Pre-Existing Drug-Resistant Mutants. Antiviral Therapy, 2008, 13, 381-388.	1.0	38
242	In Vitro Activity of 2,4-Diamino-6-[2-(Phosphonomethoxy)Ethoxy]-Pyrimidine against Multidrug-Resistant Hepatitis B Virus Mutants. Antimicrobial Agents and Chemotherapy, 2007, 51, 2240-2243.	3.2	43
243	Impact of Highly Active Antiretroviral Therapy (HAART) on the Natural History of Hepatitis B Virus (HBV) and HIV Coinfection: Relationship between Prolonged Efficacy of HAART and HBV Surface and Early Antigen Seroconversion. Clinical Infectious Diseases, 2007, 45, 624-632.	5.8	76
244	Selection of Hepatitis B Virus (HBV) Vaccine Escape Mutants in HBV-Infected and HBV/HIV-Coinfected Patients Failing Antiretroviral Drugs With Anti-HBV Activity. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 46, 279-282.	2.1	54
245	Hepatitis B virus genetic variability and evolution. Virus Research, 2007, 127, 164-176.	2.2	246
246	Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. Journal of Hepatology, 2007, 46, 531-538.	3.7	146
247	Antiviral Therapy of Chronic Hepatitis B: Prevention of Drug Resistance. Clinics in Liver Disease, 2007, 11, 869-892.	2.1	36
248	Report of an International Workshop: Roadmap for Management of Patients Receiving Oral Therapy for Chronic Hepatitis B. Clinical Gastroenterology and Hepatology, 2007, 5, 890-897.	4.4	268
249	Antiviral drug-resistant HBV: Standardization of nomenclature and assays and recommendations for management. Hepatology, 2007, 46, 254-265.	7.3	418
250	The way forward in HCV treatment — finding the right path. Nature Reviews Drug Discovery, 2007, 6, 991-1000.	46.4	267
251	Antiviral-resistant hepatitis B virus: can we prevent this monster from growing?. Journal of Viral Hepatitis, 2007, 14, 29-36.	2.0	63
252	Treatment of hepatitis B virus-infected cells with α-glucosidase inhibitors results in production of virions with altered molecular composition and infectivity. Antiviral Research, 2007, 76, 30-37.	4.1	66

#	Article	IF	CITATIONS
253	Selection of a Multiple Drug-Resistant Hepatitis B Virus Strain in a Liver-Transplanted Patient. Gastroenterology, 2006, 131, 1253-1261.	1.3	160
254	Entecavir: A new treatment option for chronic hepatitis B. Journal of Clinical Virology, 2006, 36, 8-12.	3.1	34
255	Major role of hepatitis B genotypes in liver fibrosis during coinfection with HIV. Aids, 2006, 20, 419-427.	2.2	107
256	A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine. Journal of Viral Hepatitis, 2006, 13, 278-288.	2.0	66
257	Antiviral therapy of chronic hepatitis B. Antiviral Research, 2006, 71, 206-215.	4.1	63
258	Hepatitis B virus resistance to entecavir in nucleoside naÃ ⁻ ve patients: Does it exist?. Hepatology, 2006, 44, 1404-1407.	7.3	20
259	New Nucleic Acid Diagnostic Tests in Viral Hepatitis. Seminars in Liver Disease, 2006, 26, 309-317.	3.6	25
260	In Vitro Models for Studying Hepatitis B Virus Drug Resistance. Seminars in Liver Disease, 2006, 26, 171-180.	3.6	48
261	European Multicenter Evaluation of High-Density DNA Probe Arrays for Detection of Hepatitis B Virus Resistance Mutations and Identification of Genotypes. Journal of Clinical Microbiology, 2006, 44, 2792-2800.	3.9	39
262	Long-term hepatitis B virus dynamics in HIV–hepatitis B virus-co-infected patients treated with tenofovir disoproxil fumarate. Aids, 2005, 19, 907-915.	2.2	81
263	Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology, 2005, 41, 1391-1398.	7.3	260
264	A quasi-monoclonal anti-HBs response can lead to immune escape of â€~wild-type' hepatitis B virus. Journal of General Virology, 2005, 86, 1687-1693.	2.9	30
265	Sustained HBs seroconversion during lamivudine and adefovir dipivoxil combination therapy for lamivudine failure. Journal of Hepatology, 2005, 42, 279-281.	3.7	40
266	New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. Journal of Hepatology, 2005, 42, 302-308.	3.7	216
267	Effect of a Combination of Clevudine and Emtricitabine with Adenovirus-Mediated Delivery of Gamma Interferon in the Woodchuck Model of Hepatitis B Virus Infection. Antimicrobial Agents and Chemotherapy, 2004, 48, 2683-2692.	3.2	31
268	Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic Hepatitis B virus infection. Antiviral Research, 2004, 64, 1-15.	4.1	105
269	Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy1 â~†. Gastroenterology, 2004, 126, 1750-1758.	1.3	804
270	Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic Hepatitis B virus infection. Antiviral Research, 2004, 64, 1-15.	4.1	126

#	Article	IF	CITATIONS
271	A new strategy for studyingin vitro the drug susceptibility of clinical isolates of human hepatitis B virus. Hepatology, 2004, 40, 855-864.	7.3	97
272	Management of Antiviral Resistance in Patients with Chronic Hepatitis B. Antiviral Therapy, 2004, 9, 679-693.	1.0	200
273	Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. Journal of Hepatology, 2003, 39, 1085-1089.	3.7	288
274	Treatment of pre- and post-liver transplantation HBV infection: Should we aim at combination therapy?. Hepatology, 2003, 38, 1353-1355.	7.3	19
275	Inhibitory Effect of Adefovir on Viral DNA Synthesis and Covalently Closed Circular DNA Formation in Duck Hepatitis B Virus-Infected Hepatocytes In Vivo and In Vitro. Antimicrobial Agents and Chemotherapy, 2002, 46, 425-433.	3.2	91
276	Monitoring Drug Resistance in Chronic Hepatitis B Virus (HBV)-Infected Patients during Lamivudine Therapy: Evaluation of Performance of INNO-LiPA HBV DR Assay. Journal of Clinical Microbiology, 2002, 40, 3729-3734.	3.9	146
277	Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses. Hepatology, 2002, 36, 710-722.	7.3	102
278	Duck hepatitis B virus polymerase gene mutants associated with resistance to lamivudine have a decreased replication capacity in vitro and in vivo. Journal of Hepatology, 2001, 34, 114-122.	3.7	31
279	Antiviral Activity of β- I -2′,3′-Dideoxy-2′,3′-Didehydro-5-Fluorocytidine in Woodchucks Chronically Infected with Woodchuck Hepatitis Virus. Antimicrobial Agents and Chemotherapy, 2001, 45, 1065-1077.	3.2	45
280	Early Detection of Viral Resistance by Determination of Hepatitis B Virus Polymerase Mutations in Patients Treated by Lamivudine for Chronic Hepatitis B. Hepatology, 2000, 32, 1078-1088.	7.3	197
281	Evolution of Hepatitis B Virus Polymerase Gene Sequence during Famciclovir Therapy for Chronic Hepatitis B. Journal of Infectious Diseases, 2000, 181, 1221-1233.	4.0	83
282	Characterization of the Antiviral Effect of 2′,3′-Dideoxy-2′, 3′-Didehydro-β- <scp>l</scp> -5-Fluorocytic in the Duck Hepatitis B Virus Infection Model. Antimicrobial Agents and Chemotherapy, 2000, 44, 111-122.	dine 3.2	78
283	Persistence of viral replication after anti-HBe seroconversion during antiviral therapy for chronic hepatitis B. Journal of Hepatology, 2000, 32, 307-316.	3.7	55
284	Line Probe Assay for Monitoring Drug Resistance in Hepatitis B Virus-Infected Patients during Antiviral Therapy. Journal of Clinical Microbiology, 2000, 38, 702-707.	3.9	162
285	Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance. Hepatology, 1999, 29, 230-237.	7.3	102
286	Ribavirin monotherapy in patients with chronic hepatitis C: a retrospective study of 95 patients. Journal of Viral Hepatitis, 1998, 5, 193-198.	2.0	59
287	Inhibitory Effect of 2′-Fluoro-5-Methyl-β- <scp> </scp> -Arabinofuranosyl-Uracil on Duck Hepatitis B Virus Replication. Antimicrobial Agents and Chemotherapy, 1998, 42, 369-376.	3.2	54
288	Woodchuck hepatitis virus X protein is required for viral infection in vivo. Journal of Virology, 1994, 68, 2026-2030.	3.4	430

#	Article	IF	CITATIONS
289	New assays for quantitative determination of viral markers in management of chronic hepatitis B virus infection. Journal of Clinical Microbiology, 1992, 30, 1111-1119.	3.9	31